Free tool
FAERS Monitor: Kazano
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203414 or its brand name (Kazano, Alogliptin Benzoate, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
140
Serious
62
44% of reports
Hospitalization
27
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea17
- nausea14
- drug ineffective12
- blood pressure increased10
- dyspnoea10
- heart rate increased8
- hypertension8
- pneumonia8
- blood glucose increased7
- chest pain7
- anxiety6
- back pain6
- disease recurrence6
- malaise6
- rash6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 3 |
| 2014 | 32 |
| 2015 | 21 |
| 2016 | 21 |
| 2017 | 7 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 10 |
| 2021 | 1 |
| 2022 | 12 |
| 2023 | 4 |
| 2024 | 9 |
| 2025 | 5 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,019 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease recurrenceSignal | 6 | 18.9 | 8.7 | 85 |
| heart rate increasedSignal | 8 | 12.1 | 6.2 | 71 |
| blood pressure increasedSignal | 10 | 9.8 | 5.4 | 71 |
| chest painSignal | 7 | 5.7 | 2.8 | 23 |
| hypertensionSignal | 8 | 5.7 | 2.9 | 27 |
| blood glucose increasedSignal | 7 | 5.6 | 2.7 | 22 |
| diarrhoeaSignal | 17 | 4.0 | 2.5 | 36 |
| back painSignal | 6 | 3.9 | 1.8 | 10 |
| pneumoniaSignal | 8 | 3.7 | 1.9 | 13 |
| anxietySignal | 6 | 3.2 | 1.4 | 7 |
| nauseaSignal | 14 | 2.7 | 1.6 | 13 |
| dyspnoeaSignal | 10 | 2.7 | 1.5 | 9 |
| rash | 6 | 2.1 | 0.9 | 2 |
| malaise | 6 | 2.1 | 0.9 | 2 |
| drug ineffective | 12 | 1.4 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.